Published in Mol Cancer Res on December 01, 2008
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One (2012) 1.22
Histone/protein deacetylases and T-cell immune responses. Blood (2012) 1.14
Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem (2010) 1.11
An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. J Biol Chem (2011) 0.99
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther (2013) 0.95
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One (2012) 0.91
Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. Cell Cycle (2014) 0.87
Protein modifications as potential biomarkers in breast cancer. Biomark Insights (2009) 0.87
Natural indoles, indole-3-carbinol and 3,3'-diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression. Toxicol Appl Pharmacol (2013) 0.87
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res (2015) 0.84
Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. Am J Physiol Cell Physiol (2014) 0.82
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) (2010) 0.79
Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells. PLoS One (2011) 0.79
Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. Int J Biochem Cell Biol (2014) 0.77
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discov (2017) 0.75
Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer. Oncotarget (2016) 0.75
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer. J Breast Cancer (2015) 0.75
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY) (2016) 0.75
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors. Oncotarget (2016) 0.75
Histone deacetylase 1 is essential for rod photoreceptor differentiation by regulating acetylation at histone H3 lysine 9 and histone H4 lysine 12 in the mouse retina. J Biol Chem (2016) 0.75
The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer. Cancer Cell Int (2017) 0.75
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell (2004) 5.80
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J (2002) 5.33
Nuclear hormone receptors and gene expression. Physiol Rev (2001) 4.56
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene (2007) 4.41
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol (2004) 4.24
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
Discovery and development of SAHA as an anticancer agent. Oncogene (2007) 3.58
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev (2007) 2.56
Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol (2007) 2.20
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 2.10
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
Class IIa histone deacetylases: regulating the regulators. Oncogene (2007) 1.78
HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res (2004) 1.74
Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun (2003) 1.73
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer (2003) 1.62
Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev (2006) 1.57
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther (2007) 1.55
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat (2005) 1.52
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene (2004) 1.51
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene (2004) 1.38
Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets (2005) 1.38
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett (2008) 1.37
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat (2003) 1.32
Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther (2007) 1.29
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res (2007) 1.24
Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res (2007) 1.24
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2006) 1.22
P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene (2004) 1.16
RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. J Mol Diagn (2006) 1.12
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat (2006) 1.11
Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res (2000) 1.11
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem (2004) 1.09
Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res (2006) 1.07
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol (2003) 1.05
Reporter cell lines to study the estrogenic effects of xenoestrogens. Sci Total Environ (1999) 1.00
ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene (2006) 0.97
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res (2004) 0.96
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem (2003) 0.92
Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol (2004) 0.92
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol (2004) 0.91
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell (2010) 2.89
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
Circulating epithelial cells in patients with benign colon diseases. Clin Chem (2011) 2.57
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev (2006) 2.15
Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov (2007) 1.91
An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood (2009) 1.86
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc (2010) 1.61
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer (2011) 1.47
Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev (2005) 1.46
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep (2009) 1.39
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. J Biol Chem (2004) 1.33
Activating mutations of Gsalpha in kidney cancer. J Urol (2006) 1.31
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Receptor-interacting protein 140 differentially regulates estrogen receptor-related receptor transactivation depending on target genes. Mol Endocrinol (2006) 1.27
Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci U S A (2012) 1.26
Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med (2004) 1.25
Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci (2013) 1.25
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res (2007) 1.24
Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res (2007) 1.24
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res (2009) 1.23
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2006) 1.22
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes (2012) 1.22
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol (2008) 1.21
The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene (2005) 1.21
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood (2013) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19
KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci (2011) 1.17
Sirtuins and disease: the road ahead. Front Pharmacol (2012) 1.15
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. J Mol Diagn (2006) 1.12
Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem (2010) 1.11
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proc Natl Acad Sci U S A (2011) 1.09
Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene (2002) 1.09
Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics (2012) 1.08
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem (2007) 1.08
[Clinical proteomics: towards early detection of cancers]. Med Sci (Paris) (2005) 1.07
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling. Mol Pharmacol (2006) 1.06
Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS (2011) 1.06
Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorg Med Chem Lett (2004) 1.06
Retracted Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res (2004) 1.06
The nuclear receptor transcriptional coregulator RIP140. Nucl Recept Signal (2006) 1.04
Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes (2011) 1.04
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood (2012) 1.02
Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem (2006) 1.02
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta (2008) 1.02
Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res (2010) 1.02
An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J Mol Biol (2011) 1.01
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc Res (2010) 1.01
Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition. Nucleic Acids Res (2004) 1.01
Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem (2005) 1.00
Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics (2006) 1.00
Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors. Antimicrob Agents Chemother (2004) 0.99
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol (2012) 0.99
P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N(ε)-lysine acetylation of contractile proteins. Arterioscler Thromb Vasc Biol (2012) 0.99
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des (2009) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem (2006) 0.98
Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One (2013) 0.98